ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

09 12 2023 11:00:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in December Investor Conference

01 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

03 11 2023 11:00:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

03 11 2023 11:00:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

02 11 2023 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

02 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in November Investor Conferences

30 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

26 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

16 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 9 2023 08:09:21 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in September Investor Conference

05 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Earl Douglas as General Counsel

14 8 2023 07:30:38 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

02 8 2023 15:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

26 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

15 6 2023 08:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Departure of Chief Financial Officer

14 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

09 6 2023 17:25:18 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

03 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

24 5 2023 07:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 5 2023 10:50:32 提供 Nasdaq GlobeNewswire